Agents for refractory/relapsed acute lymphocytic leukemia in adults

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Adult acute lymphoblastic leukemia (ALL) treatment outcomes have improved, but relapsed/refractory cases remain difficult.
• Patients with relapsed/refractory ALL face rapid progression, chemotherapy resistance, and high mortality.
• Achieving complete remission (CR) is rare (20-30%), with short durations unless allogeneic stem cell transplant is possible.

Purpose of the Study:

• To review major clinical advances in therapeutic agents for adult relapsed/refractory acute lymphoblastic leukemia (ALL).
• To highlight novel agents and unique strategies developed for treating this challenging patient population.

Main Methods:

• Literature review of recent clinical advances.
• Focus on therapeutic agents and strategies for refractory/relapsed ALL.

Main Results:

• Significant challenges persist in treating relapsed/refractory adult ALL.
• Median survival for these patients ranges from 2 to 12 months.
• Novel agents and therapeutic strategies are emerging.

Conclusions:

• Relapsed/refractory adult ALL presents a major therapeutic challenge.
• Recent years have seen the development of novel agents and strategies.
• This review summarizes key clinical advances in agents for refractory/relapsed ALL.